|1.||Harrington, Robert A: 11 articles (10/2015 - 03/2006)|
|2.||Bhatt, Deepak L: 10 articles (10/2015 - 12/2009)|
|3.||White, Harvey D: 10 articles (10/2015 - 12/2009)|
|4.||Mahaffey, Kenneth W: 10 articles (10/2015 - 12/2009)|
|5.||Gibson, C Michael: 10 articles (10/2015 - 12/2009)|
|6.||Stone, Gregg W: 10 articles (10/2015 - 12/2009)|
|7.||Angiolillo, Dominick J: 8 articles (10/2015 - 08/2008)|
|8.||Liu, Tiepu: 8 articles (10/2015 - 01/2012)|
|9.||Price, Matthew J: 7 articles (10/2015 - 01/2012)|
|10.||Prats, Jayne: 7 articles (10/2015 - 01/2012)|
09/01/2013 - "To reassess the efficacy of cangrelor efficacy using the universal definition of myocardial infarction (MI). "
02/01/2012 - "Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction."
03/01/2015 - "Myocardial infarction was reduced by cangrelor (37 [3.6%] vs. 59 [5.6%]; OR: 0.63, p = 0.03), as was death/myocardial infarction (39 [3.8%] vs. 61 [5.8%]; OR: 0.65, p = 0.04). "
03/01/2015 - "Because loading with a P2Y12 receptor blocker to inhibit platelets is currently the standard of care for treatment of acute myocardial infarction, we tested whether EndoIII could further reduce infarct size in rats treated with a maximally protective dose of cangrelor. "
07/01/2014 - "Effects of Cangrelor were not different against comparators for myocardial infarction (MI) (Risk ratio [RR] 0.94, 95% confidence interval [CI] 0.78-1.13) and all-cause mortality (RR 0.72, 95% CI 0.36-1.43). "
|2.||Acute Coronary Syndrome
06/01/2001 - "Phase II studies of intravenous AR-C69931MX in patients with acute coronary syndromes show that this agent has a rapid onset of action, rapidly achieving steady-state inhibition of platelet aggregation, with a half-life of only a few minutes. "
03/01/2001 - "Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes."
11/01/2013 - "Cangrelor is an intravenous P2Y12 inhibitor under investigation as an antiplatelet drug in the setting of acute coronary syndromes. "
08/01/2013 - "Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients. "
01/01/2013 - "Clinical trial data do not support the use of intravenous cangrelor or oral vorapaxar in the treatment of patients with acute coronary syndromes."
10/01/2015 - "Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials."
01/01/2015 - "The novel intravenous antiplatelet cangrelor cut thrombotic complications of PCI with some increase in bleeding, a pooled analysis of the three CHAMPION(Cangrelor versus Standard Therapy to Achieve Optimal management of Platelet Inhibition) trials showed. "
11/05/2013 - "We analyzed the bleeding rates by several previously used bleeding scales (TIMI, GUSTO, ACUITY, and BARC) after cangrelor in recent head-to-head randomized, controlled clinical trials (RCTs). "
11/05/2013 - "Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials."
10/01/2015 - "In a large clinical trial program of patients undergoing PCI, cangrelor overdosing was rare and not associated with an increase in bleeding complications, an observation that may be attributed to its very short-half life and rapid offset of action."
08/01/2015 - "The randomized, double-blind, multinational, phase III CHAMPION PHOENIX trial compared the efficacy of intravenous cangrelor with that of oral clopidogrel in patients requiring percutaneous coronary intervention (PCI) for stable angina pectoris, a non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction (MI). "
|5.||Body Weight (Weight, Body)
04/01/2013 - "We observed that continuous delivery of cangrelor at a rate of 35μg/day/kg body weight for 3days markedly decreased plasma HDL-cholesterol level, by increasing the clearance of HDL particles by the liver. "
06/01/2015 - "We aimed to assess the efficacy and safety of the P2Y12 inhibitors clopidogrel, ticlopidine, prasugrel, ticagrelor, and cangrelor according to diabetes status, age, gender, body mass index, and body weight. "
|5.||Adenosine Diphosphate (ADP)
|7.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|8.||Aspirin (Acetylsalicylic Acid)
|10.||Tissue Plasminogen Activator (Alteplase)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)